Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.250
+0.040 (0.95%)
Oct 27, 2025, 3:39 PM EDT - Market open
Larimar Therapeutics Employees
Larimar Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 23 or 54.76% compared to the previous year.
Employees
65
Change (1Y)
23
Growth (1Y)
54.76%
Revenue / Employee
n/a
Profits / Employee
-$1,535,169
Market Cap
363.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 65 | 23 | 54.76% |
| Dec 31, 2023 | 42 | 16 | 61.54% |
| Dec 31, 2022 | 26 | -5 | -16.13% |
| Dec 31, 2021 | 31 | 3 | 10.71% |
| Dec 31, 2020 | 28 | 12 | 75.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LRMR News
- 11 days ago - Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR - PRNewsWire
- 11 days ago - LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 11 days ago - Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR - Business Wire
- 4 weeks ago - Larimar Therapeutics, Inc. - Special Call - Seeking Alpha
- 4 weeks ago - Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study - Benzinga
- 4 weeks ago - Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia - GlobeNewsWire
- 4 weeks ago - Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - GlobeNewsWire
- 2 months ago - Larimar Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire